| Followers | 5 |
| Posts | 260 |
| Boards Moderated | 0 |
| Alias Born | 07/03/2025 |
Thursday, April 30, 2026 10:35:13 AM
Tasty, see below but in regards to your concern look at a calendar first. Then plug in the dates. With our votes we are seeking an adjournment followed by a nice chat where retail gets to ask questions, not Paul Choi or Jessica Fye. Wink.
Good post. Hope you vote no with us Sir.
TSS-TheSlominShield
I agree with much of your skepticism. Paul Choi’s questions on capital allocation and potential M&A were reasonable given the $308 million cash balance and current valuation, but management’s responses remained generic (“discussed regularly,” “opportunistic,” “holistic/strategic,” “report when tangible”). No timeline, no process update on Barclays, and no concrete capital-return path was provided.
The same pattern holds across the call and 10-Q: modest operational wins (U.S. branded scripts +17% YoY, new $2.8M ROW revenue, inventory down to $183.6M, positive cash flow) are welcome, but there was zero substantive disclosure on the Barclays strategic review, LREtEPA patent acceleration, EMT2 timeline, Lotus progress, or the broader global expansion strategy that Patrice Bonfiglio (Sarissa Partner and Board Member) highlighted in 2024 as a major value driver.
This is the core frustration. Sarissa took control in 2023 promising better execution and transparency than the prior regime. One year after Michael Torok joined on similar criticisms, retail still lacks visibility on the strategic items that will determine long-term value.
The May 13 AGM is our clearest, low-risk leverage point. Sarissa owns ~8%. Retail owns ~75%. Voting closes for most brokers on May 7.
Recommended plan:
• Withhold on all 7 director elections (including Torok)
• No on say-on-pay (8) and Proposals 9–12
• For on Proposal 13 (electronic delivery)
“Withhold” votes are treated as abstentions per the proxy — they create a visible public record without disrupting operations or the Barclays process. D.F. King provides near-real-time tabulations, so a strong retail turnout by May 7 will be seen immediately.
This is responsible ownership and accountability, not confrontation. After years of opportunity cost, we have every right to push for the transparency the current board promised.
Who else is voting this way? Let’s discuss constructively.
Good post. Hope you vote no with us Sir.
TSS-TheSlominShield
I agree with much of your skepticism. Paul Choi’s questions on capital allocation and potential M&A were reasonable given the $308 million cash balance and current valuation, but management’s responses remained generic (“discussed regularly,” “opportunistic,” “holistic/strategic,” “report when tangible”). No timeline, no process update on Barclays, and no concrete capital-return path was provided.
The same pattern holds across the call and 10-Q: modest operational wins (U.S. branded scripts +17% YoY, new $2.8M ROW revenue, inventory down to $183.6M, positive cash flow) are welcome, but there was zero substantive disclosure on the Barclays strategic review, LREtEPA patent acceleration, EMT2 timeline, Lotus progress, or the broader global expansion strategy that Patrice Bonfiglio (Sarissa Partner and Board Member) highlighted in 2024 as a major value driver.
This is the core frustration. Sarissa took control in 2023 promising better execution and transparency than the prior regime. One year after Michael Torok joined on similar criticisms, retail still lacks visibility on the strategic items that will determine long-term value.
The May 13 AGM is our clearest, low-risk leverage point. Sarissa owns ~8%. Retail owns ~75%. Voting closes for most brokers on May 7.
Recommended plan:
• Withhold on all 7 director elections (including Torok)
• No on say-on-pay (8) and Proposals 9–12
• For on Proposal 13 (electronic delivery)
“Withhold” votes are treated as abstentions per the proxy — they create a visible public record without disrupting operations or the Barclays process. D.F. King provides near-real-time tabulations, so a strong retail turnout by May 7 will be seen immediately.
This is responsible ownership and accountability, not confrontation. After years of opportunity cost, we have every right to push for the transparency the current board promised.
Who else is voting this way? Let’s discuss constructively.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
